All In Biotech

Drug Trial Radar · NCT04760626

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before

Effectiveness and Safety of Once Weekly Insulin Icodec Used With DoseGuide Versus Once Daily Basal Insulin Analogues in an Insulin naïve Type 2 Diabetes Population in a Clinical Practice Setting

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,085 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,085

Actual

Start

Mar 1, 2021

Primary completion

Aug 12, 2022

Study completion Aug 29, 2022

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Feb 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares insulin icodec to different daily insulins in people with type 2 diabetes. The study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily. Participants will either get insulin icodec, that participants will have to inject once a week on the same day of the week, or a marketed insulin, that participants will have to inject once a day. Which treatment participants get is decided at random. The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach. Participants will measure their blood sugar every day. Participants will get a study phone to record safety data in the electronic diary (eDiary). If participants get a daily insulin they will record their insulin doses in the eDiary. If Participants get weekly insulin icodec, participants study phone will also have the DoseGuide App. The DoseGuide App gives dose recommendations based on their blood sugar and previous doses. Participants will record their insulin doses in the DoseGuide App. The study will last for about 1 year and 2 months. Participants will have 8 planned clinic visits with the study doctor. More visits will be planned to meet individual needs. At 6 clinic visits participants will have blood samples taken. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Insulin icodecDrug

    Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.

  • Insulin Glargine 100U/mLDrug

    Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.

  • Insulin DegludecDrug

    Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.

  • Insulin Glargine 300U/mLDrug

    Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Haemoglobin (HbA1c)Time frame: Baseline (week 0), week 52

Locations

311 sites in 10 countries. Site status is shown where the registry gives one.

  • Univ of Alabama Birmingham

    Birmingham, Alabama

  • Lakeview Clinical Research, LLC

    Guntersville, Alabama

  • Pri Med Grp dba/Gil Ctr Fam

    Gilbert, Arizona

  • Lynn Institute of the Ozarks

    Little Rock, Arkansas

  • Anaheim Clinical Trials, LLC

    Anaheim, California

  • Advanced Clinical Research/Rancho Paseo Medical Group

    Banning, California

  • American Clinical Trials

    Buena Park, California

  • San Fernando Valley Hlth Inst, LLC

    Canoga Park, California

  • Med Center Medical Clinic

    Carmichael, California

  • Headlands Research California, LLC

    Escondido, California

  • Valley Research

    Fresno, California

  • Advanced Investigative Medicine, Inc.

    Hawthorne, California

  • Diabetes/Lipid Mgmt & Res Ctr

    Huntington Beach, California

  • Altman Clin & Trans Res Inst

    La Jolla, California

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • First Valley Medical Group

    Lancaster, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • Adventist Health White Memorial

    Los Angeles, California

  • Providence Clinical Research

    North Hollywood, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • Clinical Trials Research_Sacramento

    Sacramento, California

  • San Diego Family Care

    San Diego, California

  • NorCal Endocrinology and Internal Medicine

    San Ramon, California

  • Encompass Clinical Research_Spring Valley

    Spring Valley, California

  • Handelsman Yehuda

    Tarzana, California

  • Diabetes Research Center

    Tustin, California

  • Coastal Metabolic Research Center

    Ventura, California

  • Denver Endocrinology Diabetes and Thyroid Center

    Englewood, Colorado

  • Chase Medical Research LLC

    Waterbury, Connecticut

  • MedStar Diabetes Institute

    Washington D.C., District of Columbia

  • Clinical Res Of W Florida Inc

    Clearwater, Florida

  • Revival Research

    Doral, Florida

  • Est Cst Inst for Rsrch,Jksnvil

    Jacksonville, Florida

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida

  • University Of Miami

    Miami, Florida

  • Adult Medicine of Lake County, Inc

    Mt. Dora, Florida

  • Suncoast Clin Res Port Richey

    New Port Richey, Florida

  • Florida Institute for Clinical research

    Orlando, Florida

  • Palm Harbor Medical Associates

    Palm Harbor, Florida

Showing 40 of 311 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.